Please ensure Javascript is enabled for purposes of website accessibility

Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today

By Dan Caplinger - Updated Jul 8, 2019 at 4:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news on multiple fronts hit stocks.

Monday was a tough day on Wall Street, as market participants sent major benchmarks down from their recent record highs. Some investors fear that without extensive rate cuts, stocks might be overvalued, and with short-term Treasury bills on the rise, the odds of a favorable move from the Fed fell slightly. Downward pressure from several key stocks didn't help the sour mood. Deutsche Bank (DB 0.54%), Intra-Cellular Therapies (ITCI -0.75%), and Coherus BioSciences (CHRS -1.57%) were among the worst performers. Here's why they did so poorly.

Deutsche Bank makes dramatic moves

Shares of Deutsche Bank dropped 6% after the German bank announced significant restructuring efforts. The bank will get rid of its sales and trading business in equities worldwide, with sizable cuts to its investment banking business overall. In all, 18,000 jobs will go away, and Deutsche Bank will have to take an $8.3 billion restructuring charge as a result. Investors often react positively to moves like what the German bank did, but in Deutsche Bank's case, the cuts were so severe that it's far from obvious where the future growth will come from to bring about a recovery from a tough period for the financial institution.

Numerous blue flags with Deutsche Bank logo on them.

Image source: Deutsche Bank.

Intra-Cellular gets mixed results

Intra-Cellular Therapies saw its stock fall 13% following its announcement of trial results for its lumateperone treatment for bipolar depression. One of the phase 3 trials showed that the drug met its primary endpoint of improved scores on a depression rating scale, with statistically significant results in two patient groups. However, a second study failed to produce a statistically significant separation from placebo results. With high hopes for both studies, investors weren't willing to give lumateperone the benefit of the doubt, even with the company noting that positive responses to placebo were somewhat high.

Coherus reports sales figures

Finally, shares of Coherus BioSciences sank 13%. The company gave preliminary guidance for revenue from its Udenyca biosimilar treatment for cancer patients, estimating that it had sales of between $79 million and $84 million from the drug during the second quarter. Although that number was considerably higher than the consensus forecast among investors for total revenue from Coherus, some shareholders had likely hoped for even better performance, given the manufacturing volume numbers the biosimilar producer had announced earlier this month. Even with today's drop, Coherus shares have more than doubled so far this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Deutsche Bank Stock Quote
Deutsche Bank
$11.25 (0.54%) $0.06
Coherus BioSciences, Inc. Stock Quote
Coherus BioSciences, Inc.
$7.54 (-1.57%) $0.12
Intra-Cellular Therapies, Inc. Stock Quote
Intra-Cellular Therapies, Inc.
$58.28 (-0.75%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.